Objective: To analyze the long-term safety of mastoid obliteration with cartilage in children with suppurative cholesteatomatous ears. Methods: The medical records of children (≤18 years) with cholesteatomas after primary tympanomastoidectomies were performed with cartilage obliteration over a 30-year period (1982-2012) were analyzed. The recidivism rate was calculated using the Kaplan-Meier survival analysis. Potentially confounding factors of recidivism were entered into a Cox regression model as covariates for multivariate analysis. Results: Of the 150 cholesteatomatous ears in 146 children, there were 95 discharging ears (63%) in 94 children. Among the 95 discharging ears, tympanomastoidectomy was performed with cartilage obliteration (CO group) in 77 ears (81%) and without cartilage obliteration (WO group) in 18 ears (19%). The mean follow-up period was 12 years. Recidivism was observed in 16 ears in the CO group and 4 ears in the WO group. The 10-year cumulative recidivism rates were comparable between the CO and WO groups (19 vs. 25%, p = 0.762). Multivariate analysis confirmed that mastoid obliteration was not a negative predictor of recidivism (p = 0.760). Recidivism of cholesteatoma was detected within 6.5 years after surgery in the WO group and was found as late as 16.1 years after surgery in the CO group. Cartilage could be maintained in the cavity with limited resorption, preventing reretraction pockets and subsequent recidivism. Conclusion: This study provides evidence supporting the long-term safety, feasibility and effectiveness of mastoid cartilage obliteration for children with suppurative cholesteatomatous ears. Despite comparable recidivism rates between the groups, the potential for the delayed detection of recidivism with cavity obliteration may warrant long-term follow-up, with careful attention paid to the potential for recidivism during postoperative care in children. i 2014 S. Karger AG, Basel

Keywords:
Cartilage obliteration, Children, Cholesteatoma, Discharging ear, Recidivism
1.
Balyan FR, Celikkanat S, Aslan A, Taibah A, Russo A, Sanna M: Mastoidectomy in noncholesteatomatous chronic suppurative otitis media: is it necessary? Otolaryngol Head Neck Surg 1997;117:592-595.
2.
Black B: Mastoidectomy elimination: obliterate, reconstruct, or ablate? Am J Otol 1998;19:551-557.
3.
Blake CJ: The value of blood clot as a primary dressing in mastoid operations. Br Med J 1906;2:1387-1390.
4.
Cho SW, Cho YB, Cho HH: Mastoid obliteration with silicone blocks after canal wall down mastoidectomy. Clin Exp Otorhinolaryngol 2012;5:23-27.
5.
Dornhoffer JL, Smith J, Richter G, Boeckmann J: Impact on quality of life after mastoid obliteration. Laryngoscope 2008;118:1427-1432.
6.
Duncan MJ, Thomson HG, Mancer JF: Free cartilage grafts: the role of perichondrium. Plast Reconstr Surg 1984;73:916-923.
7.
Elwany MS, Radi SH, Foda HT, Magdy E, Kalsa RR: Fate of implanted autologous cartilage grafts in rabbits: an experimental histological study. Alexandria J Med 2006;42.
8.
Govaerts PJ, Raemaekers J, Verlinden A, Kalai M, Somers T, Offeciers FE: Use of antibiotic prophylaxis in ear surgery. Laryngoscope 1998;108:107-110.
9.
Heermann J: Autograft tragal and conchal palisade cartilage and perichondrium in tympanomastoid reconstruction. Ear Nose Throat J 1992;71:344-349.
10.
Irving RM, Gray RF, Moffat DA: Bone pate obliteration or revision mastoidectomy: a five-symptom comparative study. Clin Otolaryngol Allied Sci 1994;19:158-160.
11.
Kapur TR, Jayarmachandran S: Management of acquired cholesteatoma of the middle ear and the mastoid by combined approach tympanoplasty: a long-term view. Clin Otolaryngol Allied Sci 1997;22:57-61.
12.
Kay DJ, Nelson M, Rosenfeld RM: Meta-analysis of tympanostomy tube sequelae. Otolaryngol Head Neck Surg 2001;124:374-380.
13.
Kuo CL, Shiao AS, Liao WH, Ho CY, Lien CF: Can long-term hearing preservation be expected in children following cholesteatoma surgery? Results from a 14-year-long study of atticotomy-limited mastoidectomy with cartilage reconstruction. Audiol Neurootol 2012;17:386-394.
14.
Lattyak BV, Maas CS, Sykes JM: Dorsal onlay cartilage autografts: comparing resorption in a rabbit model. Arch Facial Plast Surg 2003;5:240-243.
15.
Lau T, Tos M: Cholesteatoma in children: recurrence related to observation period. Am J Otolaryngol 1987;8:364-375.
16.
Leong WS, Russell RG, Caswell AM: Stimulation of cartilage resorption by extracellular ATP acting at P2-purinoceptors. Biochim Biophys Acta 1994;1201:298-304.
17.
Lin JW, Oghalai JS: Can radiologic imaging replace second-look procedures for cholesteatoma? Laryngoscope 2011;121:4-5.
18.
Maw AR, Bawden R: The long-term outcome of secretory otitis media in children and the effects of surgical treatment: a ten-year study. Acta Otorhinolaryngol Belg 1994;48:317-324.
19.
Mishiro Y, Sakagami M, Kitahara T, Kakutani C: Prognostic factors of long-term outcomes after ossiculoplasty using multivariate analysis. Eur Arch Otorhinolaryngol 2010;267:861-865.
20.
Mokbel KM, Khafagy YW: Single flap with three pedicles, bone pate and split-thickness skin graft for immediate mastoid obliteration after canal wall down mastoidectomy. Eur Arch Otorhinolaryngol 2012;269:2037-2041.
21.
Mosher HP: A method of filling the excavated mastoid with a flap from the back of the auricle. Laryngoscope 1911;21:1158-1163.
22.
Nankivell PC, Pothier DD: Surgery for tympanic membrane retraction pockets. Cochrane Database Syst Rev 2010;7:CD007943.
23.
Nikolopoulos TP, Gerbesiotis P: Surgical management of cholesteatoma: the two main options and the third way - atticotomy/limited mastoidectomy. Int J Pediatr Otorhinolaryngol 2009;73:1222-1227.
24.
Palva T: Operative technique in mastoid obliteration. Acta Otolaryngol 1973;75:289-290.
25.
Parisier SC, Hanson MB, Han JC, Cohen AJ, Selkin BA: Pediatric cholesteatoma: an individualized, single-stage approach. Otolaryngol Head Neck Surg 1996;115:107-114.
26.
Rainsford KD: Doxorubicin is a potent inhibitor of interleukin 1 induced cartilage proteoglycan resorption in-vitro. J Pharm Pharmacol 1989;41:60-63.
27.
Ridenour JS, Poe DS, Roberson DW: Complications with hydroxyapatite cement in mastoid cavity obliteration. Otolaryngol Head Neck Surg 2008;139:641-645.
28.
Roger G, Denoyelle F, Chauvin P, Schlegel-Stuhl N, Garabedian EN: Predictive risk factors of residual cholesteatoma in children: a study of 256 cases. Am J Otol 1997;18:550-558.
29.
Roth TN, Haeusler R: Inside-out technique cholesteatoma surgery: a retrospective long-term analysis of 604 operated ears between 1992 and 2006. Otol Neurotol 2009;30:59-63.
30.
Singh V, Atlas M: Obliteration of the persistently discharging mastoid cavity using the middle temporal artery flap. Otolaryngol Head Neck Surg 2007;137:433-438.
31.
Skoog T, Ohlsen L, Sohn SA: The chondrogenic potential of the perichondrium. Chir Plast 1975;3:91-103.
32.
Spilsbury K, Miller I, Semmens JB, Lannigan FJ: Factors associated with developing cholesteatoma: a study of 45,980 children with middle ear disease. Laryngoscope 2010;120:625-630.
33.
Stangerup SE, Drozdziewicz D, Tos M, Hougaard-Jensen A: Recurrence of attic cholesteatoma: different methods of estimating recurrence rates. Otolaryngol Head Neck Surg 2000;123:283-287.
34.
Sun J, Hu Y, Lv Q, Wang Y, Li X, Xu W, Wang S, Mei Z, Wan G: Canal wall-down mastoidectomy with mastoid obliteration for pediatric cholesteatoma. Acta Otolaryngol 2010;130:259-262.
35.
Tjelmeland K, Stal S: Cartilage graft resorption: an animal model. Aesthet Surg J 2000;20:471-476.
36.
Tsai TL, Lien CF, Guo YC: Mastoid-obliteration surgery with cartilage for suppurative cholesteatomatous ears. Zhonghua Yi Xue Za Zhi (Taipei) 2002;65:523-528.
37.
Tu TY: Long-term histologic changes and effects of perichondrium preservation of auricular cartilage grafted in rabbit tympanic bullae. Audiol Neurootol 2013;18:9-16.
38.
Tu TY, Yang AH, Fan CC: Short-term effects of perichondrium preservation on chondrocyte survival and chondrogenesis of auricular cartilage grafted in rabbit tympanic bullae. Audiol Neurotol 2008;13:239-246.
39.
Ueda H, Nakashima T, Nakata S: Surgical strategy for cholesteatoma in children. Auris Nasus Larynx 2001;28:125-129.
40.
Vercruysse JP, De Foer B, Somers T, Casselman JW, Offeciers E: Mastoid and epitympanic bony obliteration in pediatric cholesteatoma. Otol Neurotol 2008;29:953-960.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.